INTRODUCTION: The Rehabilitation and Exercise Oncology model of care (ActivOnco) was established to optimize cancer survivorship through exercise prescription and active lifestyle promotion, providing a transition of care from hospital to community. Patients having any cancer diagnosis, stage of disease, and treatment were eligible for evaluation and exercise prescription upon deterioration of performance status. The team of professionals included hospital-based physiotherapists proactively screening for rehabilitation needs, loss of functional independence, and exercise eligibility, plus exercise specialists in a community-based Wellness Centre to provide follow-up or direct access for post-treatment or non-complex patients. METHODS: From January 2011 to December 2015, the hospital team assessed 1635 patients representing all major cancer sites, and the Wellness Centre team evaluated and prescribed exercise for 1066 participants. Primary interventions provided were education about fatigue management, physical activity promotion, exercise prescription, fracture risk reduction, referral to specialized follow-up services (for example, occupational therapy, lymphedema clinic), and coordination for mobility aids and paratransit services. RESULTS AND CONCLUSIONS: Implementation of the ActivOnco model of care showed that exercise alone is not a panacea for all functional deterioration associated with the cancer trajectory and its treatment. However, screening to identify rehabilitation needs combined with exercise prescription can effectively improve the quality of survivorship in cancer patients. Program developments are limited by the cost of human resources, lack of hospital-based physical resources, and lack of public funding, all of which significantly limit the scope and development of appropriate services.
INTRODUCTION: The Rehabilitation and Exercise Oncology model of care (ActivOnco) was established to optimize cancer survivorship through exercise prescription and active lifestyle promotion, providing a transition of care from hospital to community. Patients having any cancer diagnosis, stage of disease, and treatment were eligible for evaluation and exercise prescription upon deterioration of performance status. The team of professionals included hospital-based physiotherapists proactively screening for rehabilitation needs, loss of functional independence, and exercise eligibility, plus exercise specialists in a community-based Wellness Centre to provide follow-up or direct access for post-treatment or non-complex patients. METHODS: From January 2011 to December 2015, the hospital team assessed 1635 patients representing all major cancer sites, and the Wellness Centre team evaluated and prescribed exercise for 1066 participants. Primary interventions provided were education about fatigue management, physical activity promotion, exercise prescription, fracture risk reduction, referral to specialized follow-up services (for example, occupational therapy, lymphedema clinic), and coordination for mobility aids and paratransit services. RESULTS AND CONCLUSIONS: Implementation of the ActivOnco model of care showed that exercise alone is not a panacea for all functional deterioration associated with the cancer trajectory and its treatment. However, screening to identify rehabilitation needs combined with exercise prescription can effectively improve the quality of survivorship in cancerpatients. Program developments are limited by the cost of human resources, lack of hospital-based physical resources, and lack of public funding, all of which significantly limit the scope and development of appropriate services.
Entities:
Keywords:
Oncology rehabilitation; exercise; models of care; quality of life; survivorship
Authors: D Santa Mina; A Petrella; K L Currie; K Bietola; S M H Alibhai; J Trachtenberg; P Ritvo; A G Matthew Journal: Curr Oncol Date: 2015-12 Impact factor: 3.677
Authors: Prue Cormie; Daniel A Galvão; Nigel Spry; David Joseph; Raphael Chee; Dennis R Taaffe; Suzanne K Chambers; Robert U Newton Journal: BJU Int Date: 2014-07-27 Impact factor: 5.588
Authors: Mary Y Egan; Sara McEwen; Lindsey Sikora; Martin Chasen; Margaret Fitch; Susan Eldred Journal: Disabil Rehabil Date: 2013-03-15 Impact factor: 3.033
Authors: F Streckmann; S Kneis; J A Leifert; F T Baumann; M Kleber; G Ihorst; L Herich; V Grüssinger; A Gollhofer; H Bertz Journal: Ann Oncol Date: 2014-02 Impact factor: 32.976
Authors: Nicole L Stout; Alix Sleight; Denise Pfeiffer; Mary Lou Galantino; Bianca deSouza Journal: Support Care Cancer Date: 2019-03-26 Impact factor: 3.603
Authors: Nicole L Stout; Justin C Brown; Anna L Schwartz; Timothy F Marshall; Anna M Campbell; Larissa Nekhlyudov; David S Zucker; Karen M Basen-Engquist; Grace Campbell; Jeffrey Meyerhardt; Andrea L Cheville; Kelley R Covington; Jennifer A Ligibel; Jonas M Sokolof; Kathryn H Schmitz; Catherine M Alfano Journal: Cancer Date: 2020-03-25 Impact factor: 6.860
Authors: Kelley R Covington; Timothy Marshall; Grace Campbell; Grant R Williams; Jack B Fu; Tiffany D Kendig; Nancy Howe; Catherine M Alfano; Mackenzi Pergolotti Journal: Support Care Cancer Date: 2021-04-26 Impact factor: 3.603
Authors: Adriana M Coletta; Nathan B Rose; Austin F Johnson; D Scott Moxon; Stephen K Trapp; Darren Walker; Shelley White; Cornelia M Ulrich; Neeraj Agarwal; Sonal Oza; Rebecca W Zingg; Pamela A Hansen Journal: Support Care Cancer Date: 2021-01-27 Impact factor: 3.603
Authors: Louise Czosnek; Justin Richards; Eva Zopf; Prue Cormie; Simon Rosenbaum; Nicole M Rankin Journal: BMC Cancer Date: 2021-05-30 Impact factor: 4.430
Authors: Scott C Adams; Jenna Smith-Turchyn; Daniel Santa Mina; Sarah Neil-Sztramko; Prue Cormie; S Nicole Culos-Reed; Kristin L Campbell; Gemma Pugh; David Langelier; Kathryn H Schmitz; David J Phipps; Michelle Nadler; Catherine M Sabiston Journal: Front Oncol Date: 2021-07-19 Impact factor: 6.244